Skip to main content
Print Save

Uroxatral Side Effects

Generic name: alfuzosin

Medically reviewed by Drugs.com. Last updated on Jun 26, 2023.

Note: This document contains side effect information about alfuzosin. Some dosage forms listed on this page may not apply to the brand name Uroxatral.

Applies to alfuzosin: oral tablet extended release.

Serious side effects of Uroxatral

Along with its needed effects, alfuzosin (the active ingredient contained in Uroxatral) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking alfuzosin:

Rare

  • Chest pain
  • chills
  • cold sweats
  • confusion
  • dizziness, faintness, or lightheadedness when getting up from a lying or sitting position
  • fainting
  • fast, pounding, or irregular heartbeat or pulse
  • painful or prolonged erection of the penis

Incidence not known

  • Arm, back, or jaw pain
  • black, tarry stools
  • bleeding gums
  • bloody urine
  • chest discomfort, tightness, or heaviness
  • clay-colored stools
  • dark urine
  • diarrhea
  • fever
  • headache
  • hives, welts, itching, skin rash
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
  • loss of appetite
  • nausea
  • pinpoint red spots on the skin
  • stomach pain
  • sweating
  • swelling
  • unpleasant breath odor
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting of blood
  • yellow eyes or skin

Other side effects of Uroxatral

Some side effects of alfuzosin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Belching
  • body aches or pain
  • congestion
  • cough
  • cough producing mucus
  • decreased interest in sexual intercourse
  • difficulty breathing
  • difficulty having a bowel movement
  • dryness or soreness of the throat
  • ear congestion
  • heartburn
  • hoarseness
  • inability to have or keep an erection
  • indigestion
  • loss in sexual ability, desire, drive, or performance
  • loss of voice
  • nasal congestion
  • pain
  • pain or tenderness around the eyes and cheekbones
  • sneezing
  • sore throat
  • stomach discomfort or upset
  • stuffy or runny nose
  • tender, swollen glands in the neck
  • tightness in the chest
  • trouble with swallowing
  • unusual tiredness or weakness
  • voice changes

Incidence not known

  • Feeling of warmth
  • redness of the face, neck, arms, and occasionally, upper chest

For Healthcare Professionals

Applies to alfuzosin: oral tablet extended release.

Nervous system

Very common (10% or more): Dizziness (up to 27%), headache (up to 14%), fatigue (up to 14%)

Common (1% to 10%): Syncope, pain

Postmarketing reports: Flushing[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infection (up to 14%)

Common (1% to 10%): Bronchitis, sinusitis, pharyngitis

Postmarketing reports: Rhinitis[Ref]

Cardiovascular

Common (1% to 10%): Hypotension or postural hypotension

Postmarketing reports: Tachycardia, chest pain, angina pectoris in patients with preexisting coronary artery disease, atrial fibrillation[Ref]

Gastrointestinal

Common (1% to 10%): Abdominal pain, dyspepsia, constipation, nausea

Postmarketing reports: Diarrhea, vomiting[Ref]

Genitourinary

Common (1% to 10%): Impotence

Postmarketing reports: Priapism[Ref]

Ocular

Frequency not reported: Intraoperative Floppy Iris Syndrome (IFIS) has been observed in some patients undergoing phacoemulsification cataract surgery while being treated with alpha-1 blockers[Ref]

Hepatic

Postmarketing reports: Hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation)[Ref]

Dermatologic

Postmarketing reports: Rash, pruritus, urticaria, angioedema, toxic epidermal necrolysis[Ref]

Hematologic

Postmarketing reports: Thrombocytopenia

Metabolic

Postmarketing reports: Edema

References

1. Product Information. Xatral (alfuzosin). Sanofi-Synthelabo Canada Inc. 2002.

2. Product Information. Uroxatral (alfuzosin). sanofi-aventis. 2003.

3. Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. Br J Urol. 1994;74:579-84.

4. Hansen BJ, Nordling J, Mensink HJ, Walter S, Meyhoff HH. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. Scand J Urol Nephrol Suppl. 1994;157:169-76.

5. Qazi HA, Ananthakrishnan K, Manikandan R, Fordham MV. Stuttering priapism after ingestion of alfuzosin. Urology. 2006;68:890.e5-6.

6. Cerner Multum, Inc. UK Summary of Product Characteristics.

7. Wang YS, Tay YK, Kwok C. Toxic epidermal necrolysis caused by alfuzosin, an alpha1-adrenoceptor antagonist. Arch Dermatol. 2006;142:938.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer